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Abstract: Observational studies indicate that overutilization of inhaled corticosteroids (ICS)
is common in patients with chronic obstructive pulmonary disease (COPD). Overprescription
and the high risk of serious ICS-related adverse events make withdrawal of this treatment
necessary in patients for whom the treatment-related risks outweigh the expected benefits.
Elaboration of an optimal, universal, user-friendly algorithm for withdrawal of ICS therapy
has been identified as an important clinical need. This article reviews the available evidence
on the efficacy, risks, and indications of ICS in COPD, as well as the benefits of ICS
treatment withdrawal in patients for whom its use is not recommended by current guidelines.
After discussing proposed approaches to ICS withdrawal published by professional associa-
tions and individual authors, we present a new algorithm developed by consensus of an
international group of experts in the field of COPD. This relatively simple algorithm is based
on consideration and integrated assessment of the most relevant factors (markers) influencing
decision-making, such a history of exacerbations, peripheral blood eosinophil count, pre-
sence of infection, and risk of community-acquired pneumonia.
Keywords: COPD, exacerbation, inhaled corticosteroid, patient follow-up, guideline
adherence, treatment algorithm
Introduction
Chronic obstructive pulmonary disease (COPD) is a progressive chronic disease
characterized by persistent bronchial obstruction and respiratory symptoms such as
dyspnea, chronic cough, and sputum production.1 Chronic airway inflammation
plays a key role in the pathogenesis of COPD, causing narrowing of the small
airways, mucus hypersecretion, and destruction of the lung parenchyma.2
At present, there are considerable changes in approaches to prescription of inhaled
corticosteroids (ICS) in COPD.3 As has been shown in clinical trials, an ICS, usually
prescribed in a fixed-dose combination with a long-acting β2-agonist (LABA), reduces
the frequency of COPD exacerbations by an average of 25%,4 and may delay COPD
progression5 and improve disease prognosis in certain subgroups of patients.6
However, it is important to note that a significant proportion of COPD patients
will not benefit from ICS therapy. For example, Lee et al7 tested the hypothesis that
different COPD subtypes respond differently to ICS/LABA therapy, and they found
that ICS/LABA therapy provides no significant functional or clinical benefits in
comparison with LABA alone in emphysema-dominant subtype patients. Airway
inflammation in COPD is primarily neutrophil-driven,8,9 and does not respond to
ICS. Moreover, the combination of neutrophil-driven inflammation, bacterial infec-
tion, and ICS use can lead to adverse consequences.10,11
Correspondence: Sergey Avdeev
Department of Pulmonology, I.M.
Sechenov First Moscow State Medical
University, Healthcare Ministry of Russia,
Trubetskaya str., 8, Moscow 119991,
Russian Federation
Tel +7 495 708 3576
Fax +7 495 395 6393
Email serg_avdeev@list.ru
International Journal of Chronic Obstructive Pulmonary Disease Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com International Journal of Chronic Obstructive Pulmonary Disease 2019:14 1267–1280 1267
DovePress © 2019 Avdeev et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
http://doi.org/10.2147/COPD.S207775
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
19
3.
14
6.
11
5.
13
4 
on
 1
3-
Fe
b-
20
20
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
In agreement with current evidence, the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
strategy reserves ICS use as part of initial treatment for
COPD group D patients with two or more moderate
exacerbations or one exacerbation leading to hospitaliza-
tion in the preceding year and a blood eosinophil count
greater than 300 cells/µL, or as part of follow-up treatment
in COPD patients with persistent exacerbations on long-
acting bronchodilator monotherapy or LABA/LAMA
combination therapy and a blood eosinophil count greater
than 100 cells/µL.1
In the real-world environment, doctors frequently
ignore clinical guidelines and, as shown in a number of
observational studies conducted in different countries,
overutilization of ICS is common, with up to 70% of all
COPD patients receiving ICS therapy, including patients in
GOLD groups A and B (up to 35% of COPD patients).12
The recent SUPPORT study conducted in Russia also
found that the number of ICS prescriptions in real-life
practice is too high, with 33% of ICS users among
GOLD group B patients.13
The observation that ICS are overprescribed in COPD
has led to the suggestion that ICS therapy should be with-
drawn in certain patients in order to decrease the risk of
adverse effects while also reducing treatment costs.3,11,14
In this article, we provide a rationale for the withdrawal of
unnecessary ICS treatment, and suggest an algorithm to
achieve this objective.
In this paper we present a new algorithm developed by
consensus of an international group of experts. Expert selec-
tion for the inclusion into consensus panel was based on their
research activities in COPD and their previous publications
in peer reviewed journals. First of all, an expert group iden-
tified areas of uncertainty about the efficacy of ICS, possible
adverse effects associated with their use, and criteria for the
withdrawal of ICS. The meeting of the expert group was held
three times in a 6 -month period to discuss different publica-
tions on ICSwithdrawal that were considered by all members
of the committee, in order to evaluate whether these pub-
lished data could have an impact on the development of the
algorithm. Then the expert group reached a consensus on
whether to take into account the appropriate approach or if
the data presented in the analyzed article could serve as
a reference supporting this approach. In the absence of con-
sensus it was agreed to make a final solution by a simple
majority. Finally, the expert group summarized the available
evidence in response to the aforementioned questions.
Efficacy of ICS in COPD – what is
the evidence?
Early studies on ICS therapy in COPD patients failed to
demonstrate any beneficial effects on lung function and
symptom severity.15 However, an assessment of secondary
endpoints in the ISOLDE study16 showed that fluticasone
propionate did reduce the number of exacerbations in
COPD patients with severe airflow limitation (forced
expiratory volume in 1 second (FEV1) of less than 50%
predicted).17 Subsequently, this ability to prevent COPD
exacerbations was demonstrated for a number of other
ICS,18 and it was found that these drugs were effective
not only in high doses, as believed initially, but also in
moderate doses.19
A number of studies were conducted to test the hypoth-
esis that ICS therapy not only decreases the number of
exacerbations, but can also reduce mortality and delay
COPD progression. Despite a considerable body of data
accumulated over up to 3 years of follow-up, no statisti-
cally significant results have been obtained in favor of the
hypothesis, although the studies revealed a slight tendency
for increased survival in ICS (combined with LABA)
vs placebo.20,21
As ICS do not have the bronchodilator properties that
are necessary to alleviate COPD symptoms, further stu-
dies evaluated fixed-dose ICS/LABA combinations. This
treatment combination was assumed to have a good
bronchodilator effect and to be superior to bronchodila-
tor therapy alone in terms of exacerbation prevention.
However, evidence in favor of this assumption has not
been demonstrated in all studies. For example, in the
3-year TORCH study, the combination of fluticasone
propionate and salmeterol was superior to salmeterol
alone (risk ratio [RR]=0.88) in preventing moderate
and severe exacerbations in COPD patients (with
a prebronchodilator FEV1 of less than 60% predicted),
but provided no benefit when only severe exacerbations
were included in the analysis.20 Furthermore, in the
INSTEAD trial, no difference in the number of exacer-
bations was found between fluticasone/salmeterol and
indacaterol in COPD patients with moderate airflow
limitation and a history of no exacerbations in the
previous year.22 Finally, another fixed combination
(budesonide/formoterol) significantly decreased the num-
ber of exacerbations compared to formoterol, but the
effect of formoterol on the risk of exacerbations differed
little compared to placebo in these studies (all patients
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had a FEV1 of less than 50% predicted and ≥1 exacer-
bation within 2–12 months before the study).23,24
A meta-analysis of 18 randomized clinical trials found
no significant superiority of ICS/LABA combinations
over treatment with LABA alone in reducing the risk
of severe exacerbations.25
Fewer clinical studies have compared the efficacy of
ICS/LABA combinations and long-acting muscarinic ago-
nists (LAMA). Once again, no difference was found in
exacerbation rates between patients who received flutica-
sone/salmeterol and those who were treated with tiotro-
pium bromide over a 2-year period (COPD patients had
FEV1 of less than 50% predicted and a clinical history of
COPD exacerbations).26 However, significantly more
exacerbations related to an acute respiratory infection
were observed in the fluticasone/salmeterol group.
Two possible explanations may be suggested for the
inconsistent results of direct comparisons of ICS/LABA
with bronchodilator monotherapies. First, some COPD
patients may develop resistance to ICS,27 and, second,
ICS efficacy may be strongly influenced by the nature of
inflammation in the airways. A post-hoc analysis of data
obtained in a number of studies revealed a correlation
between the efficacy of ICS and eosinophil count in the
mucus and blood of COPD patients.28 In particular, it
was found that efficacy of the fluticasone furoate/vilan-
terol combination was no different from that of vilan-
terol therapy alone when eosinophil count is low and
increases on a pro rata basis as the blood eosinophil
count rises.28 A similar tendency was observed when
the extrafine beclamethasone dipropionate/formoterol
combination was compared to formoterol
monotherapy.29 The FLAME study, which compared
the number of exacerbations in COPD patients receiving
either fluticasone/salmeterol or glycopirronium/indaca-
terol for 1 year, showed that the combination of two
bronchodilator drugs was generally more effective in
decreasing the number of exacerbations (RR=0.88, inten-
tion-to-treat analysis).30 However, a post hoc analysis
based on blood eosinophil count found that the effect
of the ICS-containing combination on the number of
exacerbations was no different from that of the combina-
tion of two bronchodilator drugs in patients with high
eosinophilia (≥3% or ≥150 cells/μL).31
Although ICS have been shown conclusively in many
studies to reduce the number of exacerbations compared to
placebo, the advantage of ICS/LABA combinations over
bronchodilator drugs used as monotherapy cannot be easily
demonstrated. First, ICS are more effective in patients with
more severe lung function impairment. Second, the efficacy
of ICS in reducing the risk of exacerbations is higher on
a pro rata basis as mucus secretion and blood eosinophil
count increase and, although ICS-containing combinations
more effectively prevent exacerbations requiring ICS pre-
scription, these are a priori inferior to bronchodilator thera-
pies in preventing exacerbations associated with
a respiratory infection.26
Risks associated with ICS therapy in
COPD patients
Use of ICS in COPD patients is associated with a number of
adverse events.32 Important adverse effects of ICS therapy
include increased risks of pneumonia,33 tuberculosis (TB),
and non-tuberculous mycobacterial infections,34 osteoporo-
sis and bone fracture,35 as well as poor diabetes control36
and local reactions (such as oral candidiasis, hoarse voice,
cough, etc.) (Table 1).
Pneumonia is the most frequently reported problem in
both randomized controlled trials (RCTs) and observa-
tional studies. In a meta-analysis, Horita et al37 reported
a 43% increased risk of pneumonia in COPD patients
treated with an ICS/LABA combination compared to
LABA/LAMA (hazard ratio [HR]=0.57; 95% confidence
interval [CI]=0.42–0.79). The increased risk of pneumonia
in patients treated with an ICS, such as fluticasone and
budesonide, has attracted the attention of regulatory autho-
rities on both sides of the Atlantic.
In May 2015, the European Medicines Agency (EMA)
issued a statement declaring that a thorough analysis of the
risk of pneumonia in ICS-treated COPD patients needed to
be performed based on recent studies and meta-analyses of
earlier trials.38 This task was assigned to the
Pharmacovigilance Risk Assessment Committee (PRAC).
In March 2016, the PRAC published its report, stating that
COPD patients on ICS treatment are indeed at increased risk
of pneumonia.39 However, the PRAC experts noted that the
benefits of ICS outweighed the related risks. Furthermore,
the PRAC did not find conclusive evidence of different risks
of pneumonia associated with different types of ICS.39
It is generally accepted that long-term therapy with ICS
leads to suppression of the cellular component of the
immune system and increases susceptibility to intracellular
infections of all types. Therefore, it is interesting to assess
whether ICS use is associated with an increased risk of non-
tuberculous mycobacterial pulmonary disease (NTM-PD)
Dovepress Avdeev et al
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or tuberculosis. Brode et al34 showed that the use of ICS at
moderate and high daily doses for 1 year was associated
with an increased risk of NTM-PD, but not TB. However,
other studies have found a significant association between
ICS use and TB.34
Prospective studies on the impact of ICS on bone
mineral density in COPD patients have yielded inconsis-
tent results. A meta-analysis by Yang et al40 failed to
demonstrate any difference in bone fracture rate in patients
treated with ICS compared to placebo. In an earlier meta-
analysis, Loke et al35showed that ICS use led to a 19%
increased risk of bone fracture compared to placebo; how-
ever, this difference was not statistically significant.
In a large cohort study, ICS therapy was associated
with an increased risk of diabetes mellitus (HR=1.34;
95% CI=1.29–1.39) and of diabetes progression
(HR=1.34; 95% CI=1.17–1.53).36 The risk increased in
a dose-dependent manner and was highest in patients
who received ICS doses equivalent to fluticasone doses
of 1,000 μg/day or higher.
The existence of a moderate risk for cataract has been
shown in open-label studies in patients treated with ICS,
especially at high doses and for a long time.41 A meta-
analysis showed that the number needed to harm is 16, that
is to say that 16 patients need to be treated with ICS to
cause this adverse event in one patient [95% CI=13–19].42
Also of note is an increased risk of recurrent peptic ulcer
hemorrhages in COPD patients on ICS therapy.43
Special caution should be taken when prescribing ICS
to older COPD patients. The expected benefits should be
carefully weighed against the increased risk of adverse
events such as cataract, diabetes, pneumonia, osteoporosis,
and bone fracture.44 Furthermore, it should be kept in
mind that elderly patients can suffer from vision, hearing,
and/or coordination disturbances that may preclude proper
use of ICS-containing inhalation devices.44 Therefore,
a benefit-risk analysis is strongly recommended prior to
prescribing ICS to COPD patients, especially in those who
have risk factors for ICS-related complications.
Effects of ICS withdrawal in COPD
patients: evidence from clinical
trials
Overprescription of ICS to COPD patients and the high
risk of serious ICS-related adverse events makes withdra-
wal of this treatment necessary in patients for whom the
treatment-related risks overweigh expected benefits. The
effects of ICS withdrawal have been studied in several
randomized and non-randomized trials (Table 2).
In two randomized controlled trials (COPE and WISP),
withdrawal of fluticasone propionate led to an increase in
exacerbation risk by approximately 50% compared to
COPD patients continuing ICS treatment.45,46 However,
it should be noted that in these studies patients only
received placebo following ICS withdrawal. In all subse-
quent studies, COPD patients were switched to long-acting
bronchodilator drugs post-ICS withdrawal.
In the COSMIC trial, the effects of ICS withdrawal were
studied in 373 patients with moderate-to-severe COPD with
frequent exacerbations (two or more over the
preceding year). Following treatment with fluticasone/sal-
meterol for 3 months, one group of patients continued the
treatment while the second group was switched to salme-
terol alone.47 For 1 year, no significant difference in the
number of moderate-to-severe exacerbations was observed
Table 1 Side-effects of ICS in COPD and the type of studies
Side-effect Cohort
studies
Population-based case-
control studies
Randomized con-
trolled trials
Systematic reviews
and meta-analysis
Pneumonia + + + +
Tuberculosis + + +
Non-tuberculous mycobacterial pulmon-
ary diseases
+
Diabetes + + +
Bone fracture + + +
Cataract + + +
Peptic ulcer hemorrhages +
Local reactions (oral candidiasis, dysphonia) + + + +
Skin bruising + + +
Abbreviations: COPD, chronic obstructive pulmonary disease; ICS, inhaled corticosteroids.
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between the study groups. However, lung function was
found to be better in the ICS group (FEV1 difference=4.1%,
95% CI=1.6–6.6%).47
The INSTEAD trial included COPD patients with no
indication for ICS prescription, ie, having no severe air-
flow limitation (FEV1>50% predicted) and without
a history of exacerbations.22 Included patients must have
been on treatment with fluticasone/salmeterol for at least 3
months before ramdomization. Patients were randomized
to two groups and received either continuation with fluti-
casone/salmeterol or indacaterol for 26 weeks. The study
failed to find any difference in the number of COPD
exacerbations (RR=0.86; 95% CI=0.62–1.20) or FEV1
(the difference was 9 mL) between the groups.22
Interestingly, no deterioration in quality-of-life or symp-
tom aggravation was seen in COPD patients following ICS
withdrawal.
The INSTEAD results were reproduced in the OPTIMO
and DACCORD trials, which were conducted in the real-
world environment. The OPTIMO trial included COPD
patients with FEV1>50%, and with a history of less than
two exacerbations over the preceding year.48 The decision
to discontinue ICS therapy was made by the treating physi-
cian at enrolment. No difference was found between the
study groups in the number of exacerbations, symptom
severity, or decline of lung function after 6 months.
In DACCORD, which included 1,258 COPD patients
(mean FEV1 60% predicted), the decision to discontinue
ICS therapy was also made by the treating doctor at study
enrolment. ICS was discontinued in 19% of the study popu-
lation. The study failed to show any difference between ICS
users and non-users in the number of exacerbations and
symptom severity over 2 years of observation.49
Moreover, by the end of the 2-year period, the risk of
exacerbations was found to be lower in ICS non-users
compared to patients who were still on ICS therapy.49
The largest trial conducted thus far, WISDOM, which
included 2,485 COPD patients, compared a continued
treatment regimen with tiotropium, salmeterol, and fluti-
casone propionate to a treatment regimen which included
tiotropium, salmeterol, and a stepwise ICS dose de-
escalation (every 6 weeks) up to full withdrawal.50 All
COPD patients had severe airflow limitation (FEV1<50%
predicted) and a history of at least one exacerbation during
the year prior to enrolment. ICS withdrawal did not lead to
an increased number of COPD exacerbations compared to
continued ICS users (RR=1.06; 95% CI=0.94–1.19).
Nevertheless, ICS withdrawal led to a statistically
significant deterioration of lung function (mean FEV1
difference=38 mL), but this was not clinically relevant.
A subsequent post-hoc analysis of WISDOM data showed
that the rate of decline of lung function in COPD patients
who discontinued ICS was no different from that in
patients who continued ICS use.51 The post-hoc analysis
of the WISDOM trial found that patients with higher blood
eosinophil counts at screening were more likely to develop
exacerbations after ICS treatment was withdrawn.52
Continuation of ICS was associated with a reduced rate
of moderate or severe exacerbations in the smaller sub-
groups of patients with eosinophil counts of 300 cells/μL
or more or 4% or greater, whereas there was no difference
in exacerbation rate after discontinuation of ICS in patients
with counts of less than 4% or less than 300 cells/μL.
In the open-label, randomized CRYSTAL trial, patients
with moderate COPD and pronounced symptoms (mMRC
dyspnea score ≥1) were switched from ICS/LABA to
a fixed-dose combination of indacaterol/glycopyrronium
for 12 weeks. This resulted in an improvement of FEV1
(by 71 mL, 95% CI=36–107 mL) and a decrease in dys-
pnea severity (improvement of TDI score=1.10 units, 95%
CI=0.65–1.55 units).53
The 26-week, randomized SUNSET trial, which
involved 1,053 COPD patients, studied the effects of ICS
withdrawal in COPD patients who received triple therapy
for at least 6 months.53 COPD patients (FEV1 50–80%
predicted) with a history of at least one exacerbation over
the preceding year were randomly assigned to either tio-
tropium plus salmeterol/fluticasone or indacaterol/glyco-
pyrronium. Over the study period, no difference was
seen between study groups in the number of exacerbations
(RR=1.08; 95% CI=0.83–1.40), with a minor, clinically
irrelevant reduction of FEV1 (−26 mL; 95% CI=
−53–1 mL) observed in the ICS withdrawal group. In
a subgroup of COPD patients with peripheral blood eosi-
nophil count ≥300 cells/μL (approximately 25%), the
number of moderate and severe COPD exacerbations was
significantly higher following ICS withdrawal (RR=1.86;
95% CI=1.06–3.29), which is consistent with earlier data
indicative of a higher ICS efficacy in this patient category.
A recently published study on the efficacy and safety
of the direct switch to indacaterol/glycopyrronium from
salmeterol/fluticasone in non-frequently exacerbating
COPD patients (the FLASH trial) provided additional evi-
dence on abrupt withdrawal of ICS therapy in COPD
patients.55 In this 12-week double-blind study of 502
COPD patients it has been observed that a direct switch
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from ICS/LABA to LAMA/LABA, without a washout
period, improved lung function (pre-dose FEV1 and
FVC) in patients with moderate-to-severe COPD with up
to one exacerbation in the previous year, without new
safety signals. These results add new evidence that dual
bronchodilation is a preferable way of treatment compared
with ICS/LABA in symptomatic COPD patients with low
risk of exacerbations.
ICS withdrawal can also result in a reduction in the risk
of adverse events, particularly pneumonia. In a population-
based cohort trial, ICS withdrawal was associated with
a reduction of the risk of clinically relevant pneumonia
by 20% at 1 month and by 37% during the subsequent 3
years.56 Reduction of the risk of pneumonia was higher in
patients treated with fluticasone as compared to budeso-
nide-treated patients.54 These data show that beneficial
effects on selected outcomes (eg, pneumonia) can be
expected soon after ICS withdrawal.
Based on the results of the studies described above
(see Table 2), it can be concluded that ICS withdrawal
does not lead to a significant increase in the risk of
exacerbations in COPD patients with no prior history of
frequent exacerbations, regardless of their lung function
(ie, both in those with FEV1>50% and <50% predicted).
Moreover, ICS withdrawal results in a reduction of the
risk of adverse events, particularly pneumonia, in the
short-term. However, ICS withdrawal can have unfavor-
able effects in COPD patients who suffer from frequent
exacerbations and who have elevated eosinophil levels in
the peripheral blood.
Algorithms for ICS withdrawal in
COPD patients
As a result of overutilization of ICS in real-world practice
and with the advent of effective combined bronchodilator
therapies to treat COPD, elaboration of an optimal, uni-
versal, user-friendly algorithm for withdrawal of ICS ther-
apy appears to be important.
In recent years, some professional associations and
individual authors have designed approaches to discon-
tinue ICS. One of the first approaches for stepwise ICS
withdrawal was proposed by Kaplan.57 The proposed algo-
rithm was built on five steps and took into account:
● reviewing current management of COPD;
● evaluating the risk-benefit profile of continuing ICS
therapy, which needs considering patient history and
clinical characteristics, spirometry, sputum/blood
eosinophil, and FeNO levels for answering the ques-
tions about presence of ACO, frequent exacerbations,
and markers of eosinophilic inflammation;
● initiating stepwise ICS withdrawal based on the
patient’s current ICS dose;
● optimization of bronchodilation with LABA/LAMA
combination; and
● following-up patient every 3 months during the
first year and then annually if COPD stable and
exacerbation free.
The discussion and proposition of differential stepwise,
“hit hard”, step-up, and ICS withdrawal therapeutic
approaches for COPD patients based on their GOLD cate-
gory and sub-categories was made by a group of
Portuguese experts.58 They concluded that all approaches
are feasible and the choice of the best approach should be
based on patient careful selection and sub-categorizing,
taking into account different characteristics: initial FEV1
and worsening of FEV1 in annual assessment for category
A (AX1: FEV1>80%; no worsening of FEV1 in annual
assessment; AX2: 50%<FEV1<80%; and/or worsening of
FEV1 in annual assessment); lung function, mMRC-score,
and cardiovascular comorbidities (category B); lung func-
tion and exacerbation risk for categories C and D.
This approach is based to a certain extent on WISDOM
study and seems to be complicated for practical use.
Moreover, the authors emphasized that the proposed algorithm
will need to be validated, particularly in the real-life setting.
Another strategy has been proposed by a group of
Spanish authors.59 The first and essential condition for its
implementation is an established COPD diagnosis (criteria
for COPD diagnosis: age ≥35 years, current or past smok-
ing history ≥10 pack-years, post-bronchodilation FEV1
/FVC <0.7) with or without asthma. A concomitant diag-
nosis of asthma and COPD is made when the key diag-
nostic criteria for both diseases are met. Asthma–COPD
overlap can also be diagnosed in patients without diagnos-
tic criteria for asthma, but who have a positive broncho-
dilation test ≥400 mL and 15% FEV1 improvement and/or
eosinophil count ≥300 cells/μL.60 Patients with non-fully
reversible airflow obstruction, but with a smoking history
of fewer than 10 pack-years are classified and treated as
asthma patients.
The proposed algorithm distinguishes two categories
on opposite ends of the spectrum: patients without asthma,
with preserved lung function (FEV1>50% predicted) and
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no history of exacerbation; and patients with concomitant
asthma and a history of exacerbations. ICS therapy should
definitely be discontinued in the first group and continued
in the second. Intermediate categories, which include
patients without asthma, with FEV1>50% and exacerba-
tions, and patients with FEV1<50%, concomitant asthma,
and no history of exacerbations, require close follow-up
and the use of a differentiated approach to ICS withdrawal.
ICS withdrawal is not indicated for patients with asthma-
COPD overlap and exacerbations.
A group of authors from the UK proposed a protocol
for ICS withdrawal in COPD patients intended for primary
care physicians.61 The authors recommend caution in
applying the protocol to patients with a concomitant diag-
nosis of COPD and asthma. The protocol uses severity of
lung function impairment as its starting point. For patients
with relatively preserved lung function (FEV1≥50% pre-
dicted) and a history of frequent exacerbations (≥2 exacer-
bations over 1 year), the protocol recommends reducing
ICS dose, with due consideration for concomitant diseases
(asthma, bronchiectasis), as well as prescription of pul-
monary rehabilitation programs and monitoring of inhaler
technique. For patients with preserved lung function
(FEV1≥50% predicted) and less than two exacerbations
during the past year, an immediate switch to a LAMA/
LABA combination is recommended.
In patients with a pronounced decrease of FEV1 (<50%
predicted) and a history of exacerbations, ICS therapy
should be continued, and a reduction of the ICS dose
should be considered. For patients with a 50% decrease
in lung function and less than two exacerbations during the
past year, a switch to a fixed-dose bronchodilator drug
combination is recommended.
In order to prepare a new algorithm for ICS withdra-
wal, the international expert group reviewed a number of
significant issues related to ICS withdrawal in COPD
patients raised by Cataldo et al3 in a recent publication:
1. Only a minority of COPD patients derive benefit
from ICS therapy. These are patients with a high
benefit-to-risk ratio, including patients with
a concomitant diagnosis of COPD and asthma, as
well as patients suffering from frequent exacerba-
tions despite optimal bronchodilator therapy.
2. ICS therapy is not indicated in COPD patients:
● with a newly-diagnosed disease,
● who have developed severe adverse reactions as
a consequence of ICS therapy, and
● who have no history of exacerbations.
3. ICS withdrawal can be considered in patients who
had no apparent indication for ICS therapy in the
past. Generally, these are patients whose treatment
was initiated prior to the publication of the current
guidelines and before the advent of fixed-dose
LABA/LAMA combinations.
4. Current evidence on the topic is limited, and the
available studies are heterogeneous in terms of
study designs (randomized, controlled, or observa-
tional) and study populations (variable disease
severity and exacerbation frequency).
5. It should be remembered that no substantiated,
practical guidelines on the strategy for ICS with-
drawal, either immediate or stepwise, are avail-
able at present. Instead, there are limited data
indicating systemic symptoms that may develop
as a result of depression of endogenous steroid
production, such as those observed after ICS
withdrawal in the run-in period in the ISOLDE
study.62 On the other hand, the level of patient
acceptance of ICS therapy is low in the real-world
environment, resulting in poor adherence to the
prescribed treatment.11,61,63
Cataldo et al3 proposed a fairly simple algorithm based on
exacerbation history. The authors suggest that patients
with no history of exacerbations during the
preceding year (approximately 75% of the DACCORD
study population)64 who are treated with either an ICS/
LABA/LAMA or an ICS/LABA combination may benefit
from ICS withdrawal and a switch to a double bronchodi-
lator therapy.
A different approach should be applied in patients with
a history of exacerbations during the previous 12 months
(25% of the DACCORD study population).64 If the patient
was on triple therapy, prescription of an add-on therapy
and ICS dose correction should be considered. If the
patient was receiving an ICS/LABA combination, modifi-
cation of the treatment regimen is recommended by either
adding a LAMA or by switching the patient to a LAMA/
LABA combination.
Finally, the new GOLD 2017 classification has not
included the FEV1 in the initial classification of symptoms
and risk, and, therefore, a significant number of patients
originally classified as D according to GOLD 2013 will
now be classified as B, indicating low level of risk. In this
case, patients newly classified as B according to GOLD 2017
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should be discontinued from ICS if they have less than 300
eosinophils/μL.65
This is a selective and far from complete list of approaches
to withdrawal of unnecessary ICS, as defined in currently
available clinical guidelines. The expert group held several
working group meetings in order to formulate approaches to
ICS withdrawal in COPD patients.66–68 The expert team
reviewed available approaches to (and algorithms for) ICS
withdrawal and switching to treatment regimens without ICS.
It was emphasized that any attempt to include more factors
than are considered in the currently available protocols would
inevitably lead to an oversophisticated algorithm that would
be difficult to use in everyday clinical practice. On the other
hand, oversimplification of the approach by minimizing the
number of the factors would not allow for all possible clinical
situations to be covered. In view of the above, the working
group tried to use an integrated approach to formulate
a relatively simple algorithm that is based on consideration
and integrated assessment of the most relevant factors (mar-
kers) influencing decision-making, such as a history of
exacerbations, peripheral blood eosinophil count, presence
of infection, and risk of community-acquired pneumonia.66–68
In the algorithm proposed (see Figure 1), stable COPD,
ie, the absence of exacerbations in the previous 3 months, is
the essential prerequisite for further therapy revision in
COPD patients without concomitant asthma. Once the
above requirement is met, blood eosinophil count is used
as the main marker to guide decision-making. If the blood
eosinophil count is below a cut-off value of 300 cells/μL,
ICS withdrawal is appropriate for patients treated with an
ICS/LABA, ICS/LAMA, or ICS/LABA/LAMA triple
combination.
For patients with a blood eosinophil count above a cut-
off value of 300 cells/μL, the treatment strategy should be
based on whether the patient has a history and risk of
infectious exacerbations and/or community-acquired pneu-
monia, which is indicative of a high risk of occurrence of
these conditions in the future.56 Factors associated with
a significant increase in the risk of ICS associated pneumo-
nia could be defined as: being a current smoker, having prior
pneumonia, body mass index <25 kg/m2, and severe airflow
limitation (FEV1<50%).69 A large population-based cohort
trial demonstrated that reduction of the risk of pneumonia
can be expected soon after ICS withdrawal.56
Patients with persistent exacerbations despite ICS treat-
ment and features of so called “infective phenotype“ (fre-
quent bacterial exacerbations, chronic bacterial
colonization, bronchiectasis)70 can also require ICS
Figure 1 A proposed algorithm for ICS withdrawal in patients with COPD.
Abbreviations: BA, bronchial asthma; CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; EOS, eosinophils; ICS, inhaled corticosteroid;
LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist.
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reduction or withdrawal, and additional use of long-term
antibiotics has been advocated in these patients.71
ICS dose reduction as a way of treatment modification
(rather than withdrawal) would be a reasonable therapeutic
option for many COPD patients, for example, with high
eosinophil counts and a history/risk of pneumonia and
infectious exacerbations.
This ICS reduction step of the decision-making tree can be
justified by previously shown predominantly anti-
inflammatory effects related to modulation of the humoral
components of the innate immune response, which may lead
to reduced airway bacterial load and lower risk of
pneumonia.10,72
The concept of switching to ICS with lower risk of side-
effects (SE) is based on data which demonstrated substan-
tially increased risk of pneumonia with using of more potent
and lipophilic ICS such as fluticasone propionate or flutica-
sone furoate, but not beclometasone dipropionate or
budesonide.73,74 It is possible that the differences observed
in the incidence of pneumonia reflect the dose of ICS used.
Almost all salmeterol/fluticasone trials used fluticasone 500
μg bid, whereas all the budesonide/formoterol trials used
budesonide 320 μg bid. (Dose equivalences used are beclo-
methasone 1,000 μg, budesonide 800 μg, fluticasone propio-
nate 500 μg, and fluticasone furoate 100 μg).
So, in COPD patients with history and/or increased risk
of pneumonia and/or infectious exacerbations, it’s reason-
able to change ICS to a molecule with lower risk of side-
effects (eg, from fluticasone to budesonide or
beclomethasone).74,75
ICS withdrawal is not recommended for COPD
patients with high eosinophil counts without a risk of
infectious exacerbations and/or community-acquired
pneumonia.
Conclusion
Common overutilization and the high risk of serious treatment-
related adverse events make withdrawal of this ICS therapy
necessary in COPD patients for whom its use is not recom-
mended by current guidelines. Practical implementation of ICS
withdrawal in everyday clinical practice for clinicians is
needed in the management of COPD patients. The ICS with-
drawal algorithm developed by an expert group provides
a user-friendly yet comprehensive integrated assessment of
the most relevant factors influencing decision-making, such
as a history of exacerbations, peripheral blood eosinophil
count, presence of infection, and risk of community-acquired
pneumonia.
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